OncoMatch/Clinical Trials/NCT06730256
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Is NCT06730256 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CAR-T cells Infusion chimeric antigen receptor T cells for relapsed/refractory plasma cell leukemia.
Treatment: CAR-T cells Infusion chimeric antigen receptor T cells — A Clinical Study to Explore the Safety, Efficacy, and Cellular Metabolic Dynamics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Patients with R/RMM who have received at least 3 prior lines of therapy, including at least 1 proteasome inhibitor and at least 1 immunomodulator (IMiD)
Must have received: immunomodulator
Patients with R/RMM who have received at least 3 prior lines of therapy, including at least 1 proteasome inhibitor and at least 1 immunomodulator (IMiD)
Must have received:
Patients with RRpPCL had received at least 1 prior line of therapy
Cannot have received: allogeneic stem cell transplant
Previous allogeneic stem cell transplantation
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks prior to signing informed consent
autologous stem cell transplantation within 12 weeks prior to signing informed consent
Cannot have received:
Exception: treatment for the disease within 14 days before informed consent
Have received treatment for the disease within 14 days before informed consent
Cannot have received: cell therapy
Exception: within 28 days before informed consent
Have received cell therapy within 28 days before informed consent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06730256 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant, autologous stem cell transplant, disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages